Genomics and Transcriptional Core supports MUCOR mycosis research across teams
Official title: Genomics and Transcriptional Core
Funded at Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · NIH-11364084 · Data updated 2026-11-12
A genomics and transcriptomics core is joining a large project to study how the immune system and the fungus mucor interact, aiming to improve diagnosis and treatment of mucormycosis.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center NIH-funded |
| Lab location | 1 site (Torrance, United States) |
| Project start | July 1, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $713,185 |
| NIH project number | 5P01AI186818-02 |
| Project ID | NIH-11364084 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with mucormycosis or those at risk may benefit from improved diagnostics and therapies arising from this research.
✕Less likely to help
Direct clinical benefits may not be immediate for all participants, as this is a multi-year research core component.
What this research studies
This program project centers on understanding how mucormycosis develops and how host and fungal factors drive outcomes, using high-throughput sequencing of host and pathogen RNA and genomes. The Genomics/Transcriptomics Core will perform single-cell RNA sequencing, bulk RNA sequencing, and long-read genome sequencing, producing reference genomes and detailed data analyses. Data management and sharing will be organized to ensure researchers can interpret results and translate them into potential clinical tools. The work involves in vivo and in vitro models, advanced sequencing technologies, and collaboration across multiple projects at an established biomedical center.
Why it matters
Potential benefit: If successful, the project could lead to better risk stratification, more accurate diagnostics, and new therapeutic approaches for mucormycosis.
How similar studies have gone: Previous mucormycosis research has advanced understanding of host-pathogen interactions, and this core aims to extend that success with newer sequencing approaches.
Where this research is happening
-
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, United States Active
Researchers
- Principal investigator: Bruno, Vincent Michael — Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Study coordinator: Bruno, Vincent Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.